The Limitations of a Hypothetical All-Variant COVID-19 Vaccine: A Simulation Study

• Published in: Vaccines (Basel) Vol. 12; no. 5; p. 532
• Main Author: Kosinski, Robert J
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 01-05-2024
• Subjects: Analysis; Antigens; compartmental model; Coronaviruses; COVID-19; COVID-19 vaccines; Disease control; Disease transmission; Epidemics; epidemiology; Health aspects; Herd immunity; Hospitalization; Immunity; Infection; Infectivity; Medical research; Medicine, Experimental; Pandemics; Public health; SARS-CoV-2; Severe acute respiratory syndrome coronavirus 2; Simulation; Simulation methods; Subpopulations; Success; Vaccination; Vaccines; Viral diseases; United States > US; COVID-19; epidemiology; SARS-CoV-2; compartmental model
• ISSN: 2076-393X; 2076-393X
• DOI: 10.3390/vaccines12050532

This paper simulates a hypothetical pan-coronavirus vaccine that confers immediate sterilizing immunity against all SARS-CoV-2 variants. Simulations used a SEIIS (susceptible, exposed, infective, immune, susceptible) spreadsheet model that ran two parallel subpopulations: one that accepted vaccination and another that refused it. The two subpopulations could transmit infections to one another. Using data from the United States (US), the simulated vaccine was tested against limiting factors such as vaccine hesitancy, slow vaccination distribution, and the development of high-transmission variants. The vaccine was often successful at reducing cases, but high-transmission variants and discontinuation of non-pharmaceutical interventions (NPIs) such as masking greatly elevated cases. A puzzling outcome was that if NPIs were discontinued and high-transmission variants became common, the model predicted consistently higher rates of disease than are actually observed in the US in 2024. However, if cumulative exposure to virus antigens increased the duration of immunity or decreased the infectivity of the virus, the model predictions were brought back into a more realistic range. The major finding was that even when a COVID-19 vaccine always produces sterilizing immunity against every SARS-CoV-2 variant, its ability to control the epidemic can be compromised by multiple common conditions.